Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...

Abrysvo® and Arexvy® are Health Canada-approved vaccines for preventing RSV-related lower respiratory tract disease in individuals 60 years of age and older, currently available for high-risk older ...

There is also a vaccine called Abrysvo under the brand name and RSVpreF under the generic name, for pregnant women between 32 ...

Free shots that can protect babies from respiratory syncytial virus are being offered by some health-care providers in ...

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

(This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the ...